Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 5, 1998, Pages 484-491

  Arlander, Eva ^a   Ekström, Gunilla ^b   Alm, Christina ^b   Carrillo, Juan Antonio ^b   Bielenstein, Margareta ^b   Böttiger, Ylva ^b   Bertilsson, Leif ^b   Gustafsson, Lars L ^b  

^a Research and Development at Scania Technical Centre   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; KETOCONAZOLE; PHENACETIN O DEETHYLASE; ROPIVACAINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; IN VIVO STUDY; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; NAUSEA; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; URINARY EXCRETION;

EID: 0031775019     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90131-X     Document Type: Article

References (30)

1. McClure JH. Ropivacaine. Br J Anaesth 1996;76:300-7.
2. Arlander E, Löfberg R, Ståhlberg D, Öst A, Sjövall J. Ropivacaine gel in active distal ulcerative colitis: pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996;10:73-81.
3. Arvidsson T, Forsmo Bruce H, Halldin MM. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral-AGP column. Chirality 1995;7:272-7.
4. Emanuelsson BM, Persson J, Sandin S, Alm C, Gustafsson LL. Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects. Ther Drug Monk 1997;19:126-31.
5. Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB. Disposition kinetics of ropivacaine in humans. Anesth Analg 1989;69:736-8.
6. Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, et al. Metabolism and excretion of ropivacaine in humans. Drug Metab Dispos 1996;24:962-8.
7. Ekström G, Gunnarsson UB. Ropivacaine, a new amide type local anaesthetic agent is metabolised by cytochromes P450 1A and 3A4 in human liver microsomes. Drug Metab Dispos 1996;24:955-61.
8. Shimada T, Yamazaki H, Miamura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
9. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:3-29.
10. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
11. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
12. Spina E, Pollicino AM, Avenoso A, Campo GM, Perruca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15:243-6.
13. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-83.
14. Gomez DY, Wacher VJ, Tomlanovich SJ, Herbert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
15. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
16. Sonino N, Oates JA, Wood A. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812-8.
17. Böttiger Y, Tybring G, Götharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997;62:384-91.
18. Bertilsson L, Carrillo AJ, Dahl ML, LLerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
19. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodrígues I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 but also CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
20. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304.
21. Bertilsson L, Lou Y, Du Y, Liu Y, Kuang T, Liao X, et al. Pronounced differences between native Chinese and Swedish populations of debrisoquine and s-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
22. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-11.
23. 3]-ropivacaine in biological samples by gas chromatography with nitrogen phosphorus detection or mass spectrometry. J Chromatogr 1998;709:57-67.
24. Arvidsson T, Eklund E. Determination of free concentration of ropivacaine in blood plasma by ultrafiltration and coupled column liquid chromatography. J Chromatogr 1995;668:91-8.
25. Rowland M, Tozer T. Clinical pharmacokinetics, concepts and applications. 3rd ed. Baltimore: Williams and Wilkins, 1995.
26. Jones B, Kenward KG. Design and analysis of crossover trials. New York: Chapman-Hall; 1989.
27. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: John Wiley; 1987.
28. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19 catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
29. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
30. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58: 399-403.